13F Holdings
中文EN

AMPH Amphastar Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1297184 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.1%
TTM net income YoY-11.3%
TTM EPS YoY-3.5%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR-9.9%

Margins

Gross margin46.8%
Operating margin18.7%
Net margin13.3%
FCF margin18.6%
EBITDA margin22.4%

Returns

ROE12.4%
ROA5.9%
ROIC (approx.)8.9%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets52.4%
Debt / equity0.75x
Current ratio3.32x
Interest coverage5.25x

Cash quality & payout

Operating cash flow / net income1.77x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue4.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$207.61M$183.90M$171.17M$183.10M$191.84M$174.41M$170.53M$186.52M
Cost of revenue$107.98M$90.43M$100.85M$97.44M$93.19M$87.92M$85.28M$99.88M
Gross profit$99.63M$93.47M$70.32M$85.67M$98.65M$86.49M$85.25M$86.65M
R&D expense$20.08M$22.16M$26.74M$23.31M$22.35M$20.08M$20.10M$18.14M
SG&A expense$16.84M$18.24M$18.03M$16.47M$39.47M$13.99M$16.00M$12.94M
Operating income$50.77M$39.73M$13.63M$35.61M$25.32M$42.18M$37.29M$45.14M
Interest expense$6.76M$6.66M$6.55M$6.63M$6.28M$6.28M$6.29M$6.42M
Pretax income$49.06M$38.54M$10.05M$31.91M$21.51M$39.34M$30.86M$43.96M
Income tax$11.30M$8.20M$3.63M$7.49M$4.16M$8.30M$5.58M$6.00M
Net income$37.76M$30.35M$6.42M$24.43M$17.35M$31.03M$25.29M$37.96M
EBITDA$66.36M$54.04M$21.71M$24.90M$39.45M$56.80M$44.66M$44.26M
EPS (basic)0.890.690.14—0.380.660.53—
EPS (diluted)0.870.670.14—0.370.640.51—
Weighted avg. shares (diluted)43.38M44.23M46.46M—47.68M48.13M49.89M—
Balance sheet
Cash & equivalents$204.59M$223.61M$170.94M$170.18M$216.50M$187.92M$183.02M$151.84M
Short-term investments$26.05M$66.51M$121.01M$112.64M$59.94M$44.06M$54.10M$70.04M
Receivables$182.22M$144.86M$147.85M$143.56M$146.81M$132.98M$144.64M$136.29M
Inventory$173.92M$179.91M$170.19M$176.89M$185.93M$191.73M$185.48M$153.74M
Current assets$602.68M$630.95M$633.68M$636.02M$639.47M$580.83M$587.96M$534.07M
PP&E, net$312.87M$316.06M$307.23M$310.57M$308.69M$310.24M$307.60M$297.35M
Goodwill$3.30M$3.31M$3.33M$3.40M$3.40M$3.40M$3.16M$3.05M
Intangibles$607.90M$615.30M$527.07M$533.34M$539.61M$545.88M$552.15M$558.39M
Total assets$1.71B$1.74B$1.65B$1.63B$1.67B$1.62B$1.63B$1.58B
Current liabilities$181.43M$263.20M$164.48M$158.16M$205.23M$176.41M$199.05M$173.76M
Short-term debt$2.50M$2.49M$1.67M$1.64M$923,000$927,000$224,000$234,000
Long-term debt$610.50M$609.56M$609.80M$608.75M$608.58M$607.73M$603.86M$601.63M
Total debt$613.00M$612.05M$611.47M$610.39M$609.50M$608.65M$604.08M$601.86M
Total liabilities$897.17M$975.61M$874.77M$840.49M$889.48M$857.85M$874.99M$845.17M
Shareholders' equity$814.55M$768.16M$773.39M$788.80M$776.75M$757.48M$751.28M$732.30M
Net debt$408.41M$388.44M$440.53M$440.21M$393.00M$420.73M$421.06M$450.02M
Shares outstanding42.65M42.53M44.64M45.65M46.35M46.49M47.67M47.62M
Cash flow statement
Operating cash flow$43.30M$51.32M$47.84M$32.86M$52.58M$35.59M$35.08M$29.02M
Capital expenditure$9.94M$8.59M$9.51M$8.27M$5.35M$10.56M$10.70M$12.41M
Free cash flow$33.36M$42.73M$38.33M$24.59M$47.23M$25.03M$24.38M$16.61M
Investing cash flow-$63.96M$44.87M-$16.73M-$60.57M-$19.62M-$625,000$10.48M-$35.68M
Financing cash flow$1.71M-$43.53M-$30.21M-$18.37M-$4.35M-$30.20M-$14.50M-$33.84M
Depreciation & amortization$15.58M$14.31M$8.08M-$10.71M$14.13M$14.62M$7.37M-$882,000
Stock-based compensation$7.01M$7.09M$9.27M$6.21M$6.30M$6.38M$8.39M$5.63M
Share buybacks$438,000$45.21M$29.49M$20.52M$4.85M$39.22M$11.00M$42.00M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.